Role of osteopontin in tumour progression

por Rittling, S R, Chambers, A F
Publicado 2004

Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response

por Thoms, J W, Dal Pra, A, Anborgh, P H, Christensen, E, Fleshner, N, Menard, C, Chadwick, K, Milosevic, M, Catton, C, Pintilie, M, Chambers, A F, Bristow, R G
Publicado 2012